Novartis settles sex discrimination case as second quarter beats expectations
This article was originally published in Scrip
Executive Summary
Novartis's strong performance in the second quarter has been tarnished somewhat by its settlement of a discrimination case that was brought in 2004.
You may also be interested in...
Women Wanted: Merck Faces Class Action In $250m Discrimination Case
A handful of former female sales representatives suing Merck & Co. Inc. for gender discrimination, including an alleged bias against employees who took maternity leave, could become a very large group of women now that the lawsuit seeking $250m in damages has been granted conditional certification as a collective action under the Equal Pay Act (EPA).
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.